- Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal
- The extract, Tilray Oral Solution THC10:CBD10, also known as Tilray Solução Oral THC10:CBD10, is now approved for medical use in Portugal
- This follows the approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year
- Tilray stock (TSX:TLRY) last traded at C$2.60 per share
Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.
The extract, Tilray Oral Solution THC10:CBD10, also known as Tilray Solução Oral THC10:CBD10, is now approved for medical use in Portugal.
“This is a significant step towards meeting the critical needs of patient care and providing high-quality cannabis products and therapeutic options to those with specific medical…
